Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-29T18:11:10.045Z Has data issue: false hasContentIssue false
  • English
  • Français

COST-EFFECTIVENESS ANALYSIS OF CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WITH NYHA I AND NYHA II HEART FAILURE IN SPAIN

Published online by Cambridge University Press:  03 April 2013

Luis Almenar ,
Beatriz Díaz ,
Aurelio Quesada ,
Carlos Crespo ,
Belén Martí ,
Stuart Mealing ,
Cecilia Linde  and
Claude Daubert
Luis Almenar
Affiliation:
Cardiology Department, Hospital Universitario La Fe
Beatriz Díaz
Affiliation:
Cardiology Department, Hospital Universitario Central de Asturias
Aurelio Quesada
Affiliation:
Cardiology Department, Hospital General de Valencia
Carlos Crespo
Affiliation:
Department of statistics, University of Barcelona Oblikue Consulting
Belén Martí
Affiliation:
Health Economics and Reimbursement, Medtronic Ibérica
Stuart Mealing
Affiliation:
Oxford Outcomes
Cecilia Linde
Affiliation:
Department of Cardiology, Karolinska University Hospital
Claude Daubert
Affiliation:
Département de Cardiologie et maladies vasculaires, CHU
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The aim of the study was to combine clinical results from the European Cohort of the REVERSE study and costs associated with the addition of cardiac resynchronization therapy (CRT) to optimal medical therapy (OMT) in patients with mild symptomatic (NYHA I-II) or asymptomatic left ventricular dysfunction and markers of cardiac dyssynchrony in Spain.

Methods: A Markov model was developed with CRT + OMT (CRT-ON) versus OMT only (CRT-OFF) based on a retrospective cost-effectiveness analysis. Raw data was derived from literature and expert opinion, reflecting clinical and economic consequences of patient's management in Spain. Time horizon was 10 years. Both costs (euro 2010) and effects were discounted at 3 percent per annum.

Results: CRT-ON showed higher total costs than CRT-OFF; however, CRT reduced the length of hospitalization in ICU by 94 percent (0.006 versus 0.091 days) and general ward in by 34 percent (0.705 versus 1.076 days). Surviving CRT-ON patients (88.2 percent versus 77.5 percent) remained in better functional class longer, and they achieved an improvement of 0.9 life years (LYGs) and 0.77 years quality-adjusted life years (QALYs). CRT-ON proved to be cost-effective after 6 years, except for the 7th year due to battery depletion. At 10 years, the results were €18,431 per LYG and €21,500 per QALY gained. Probabilistic sensitivity analysis showed CRT-ON was cost-effective in 75.4 percent of the cases at 10 years.

Conclusions: The use of CRT added to OMT represents an efficient use of resources in patients suffering from heart failure in NYHA functional classes I and II.

Keywords

Cardiac resynchronization therapyREVERSECost-effectiveness analysisLeft ventricleHeart failure
Type
ASSESSMENTS
Information
International Journal of Technology Assessment in Health Care , Volume 29 , Issue 2 , April 2013 , pp. 140 - 146
Copyright
Copyright © Cambridge University Press 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Dickstein, K, Cohen-Solal, A, Filippatos, G, et al.European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008;29:2388–2442.Google Scholar
2.Banegas, JR, Rodríguez-Artalejo, F, Guallar-Castillón, P.[Epidemiological situation of heart failure in Spain]. Rev Esp Cardiol. 2006;6 (Suppl C):4–9.CrossRefGoogle Scholar
3.National Statistics Institute (INE). Deaths by cause of death 2008. www.ine.es (accessed June 1st, 2010).Google Scholar
4.Sánchez, V, Cavero, MA, Delgado, JF, Pulpón, LA. [Cardiac resynchronization therapy: Point of view of clinical cardiologist]. Rev Esp Cardiol. 2005;5 (Suppl B):53–59.Google Scholar
5.Gomez-Soto, FM, Andrey, JL, García-Egido, AA, et al.Incidence and mortality of heart failure: A community-based study. Int J Cardiol. 2011;151:40–45.CrossRefGoogle ScholarPubMed
6.Callejo, D, Guerra, M, Hernández-Madrid, A, Blasco, JA.Economic assessment of cardiac resynchronization therapy. Rev Esp Cardiol. 2010;63:1235–1243.CrossRefGoogle ScholarPubMed
7.Calvert, MJ, Freemantle, N, Yao, G, et al.Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J. 2005;26:2681–2688.CrossRefGoogle ScholarPubMed
8.Silva, L, García-Pavía, P, Ortigosa, J.[Resynchronization and prevention of sudden death in heart failure. From clinical trials to clinical practice]. Rev Esp Cardiol. 2006;6 (Suppl F):59–70.Google Scholar
9.Daubert, C, Gold, MR, Abraham, WT, et al.Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from de European cohort of REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009;54;1837–1846.CrossRefGoogle ScholarPubMed
10.Moss, AJ, Jackson, W, Cannom, DS, Klein, H, Brown, MW, MADIT-CRT trial investigators. Cardiac-resynchronization therapy for the prevention of heart failure events. N Engl J Med. 2009;361:1329–1338.CrossRefGoogle ScholarPubMed
11.Linde, C, Mealing, S, Hawkins, N, et al.Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction). Eur Heart J. 2011;32:1631–1639.CrossRefGoogle ScholarPubMed
12.Fox, M, Mealing, S, Anderson, R, et al.The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Health Technol Assess. 2007;11:11–68, iii-iv, ix-248.CrossRefGoogle ScholarPubMed
13.EUCOMED. Medical device price report Q2 2009-Q1 2010. www.eucomed.org (accessed June 1st, 2010).Google Scholar
14.E-salud. Spanish health cost data base. Barcelona, 2010. http://www.oblikue.com (accessed June 1st, 2010).Google Scholar
15.Spanish General Council of Official Colleges of Pharmacists. Spanish drug price database. Bot Plus Web, 2010. https://botplusweb.portalfarma.com/ (accessed June 1st, 2010).Google Scholar
16.Sacristán, JA, Oliva, J, Del Llano, J, Prieto, L, Pinto, JL.What is an efficient health technology in Spain? Gac Sanit. 2002;16:334–343.CrossRefGoogle ScholarPubMed
17.Feldman, AM, de Lissovoy, G, Bristow, MR, et al.Cost effectiveness of cardiac resynchronisation therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005;46:2311–2321.CrossRefGoogle ScholarPubMed
18.National Institute for Clinical Excellence (NICE). Cardiac resynchronization therapy for the treatment of heart failure. NICE technology appraisal guidance 120. 2007. www.nice.org.uk/TA120 (accessed June 1st, 2010).Google Scholar
19.St John Sutton, MG, Plappert, T, Abraham, WT, et al.Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003;107:1985–1990.CrossRefGoogle ScholarPubMed
20.Higgins, SL, Hummel, JD, Niazi, IK, et al.Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42:1454–1459.CrossRefGoogle ScholarPubMed
21.Alonso, C, Ritter, P, Leclercq, C, et al.Effects of cardiac resynchronization therapy on heart rate variability in patients with chronic systolic heart failure and intraventricular conduction delay. Am J Cardiol. 2003;91:1144–1147.CrossRefGoogle ScholarPubMed
22.Yao, G, Freemantle, N, Calvert, MJ, et al.The long term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J. 2007;28:42–51.CrossRefGoogle ScholarPubMed
23.Muñoz, R, Martínez-Ferrer, J, Delgado, J, et al.[Can cardiac resynchronization therapy added to optimize pharmacological treatment make up in patients with heart failure in Spain?]. PharmacoEconomics Sp Res Art. 2010;7:13–25.CrossRefGoogle Scholar
24.Tang, AS, Wells, GA, Talajic, M, et al.Resynchronization-defibrillation for ambulatory heart failure trial investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–2395.CrossRefGoogle Scholar
25.Calvert, MJ, Freemantle, N, Cleland, JG.Cardiac resynchronisation therapy is cost effective. Rev Esp Cardiol. 2010;63:1230–1231.CrossRefGoogle ScholarPubMed
Supplementary material: File

Almenar et al. supplementary material

Supplementary figure 1

Download Almenar et al. supplementary material(File)
File 50.7 KB